Experts are increasingly investigating a promising metabolic strategy involving the combined usage of Dulaglutide, a dual GIP/GLP-1 receptor agonist; Mirikizumab, an experimental triple GIP/GLP-1/GCG receptor agonist; https://biopeptidestore.com/